Oramed Pharmaceuticals Files 8-K: Other Event

Ticker: ORMP · Form: 8-K · Filed: Mar 19, 2024 · CIK: 1176309

Oramed Pharmaceuticals Inc. 8-K Filing Summary
FieldDetail
CompanyOramed Pharmaceuticals Inc. (ORMP)
Form Type8-K
Filed DateMar 19, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.012, $101,875,000, $5 million, $15 million, $11.5 million
Sentimentneutral

Sentiment: neutral

Topics: other-event, filing-update

Related Tickers: ORMP

TL;DR

ORMP filed an 8-K for an 'Other Event' on 3/14. Details TBD.

AI Summary

On March 14, 2024, Oramed Pharmaceuticals Inc. filed an 8-K report detailing an "Other Event." The filing does not provide specific details about the event itself, but it was submitted on March 19, 2024, with the earliest reported event date being March 14, 2024. The company's principal executive offices are located at 1185 Avenue of the Americas, New York, NY.

Why It Matters

This filing indicates a material event has occurred for Oramed Pharmaceuticals, requiring disclosure to investors. The lack of detail in the filing itself necessitates further investigation to understand the event's implications.

Risk Assessment

Risk Level: medium — The filing indicates a material event has occurred, but the lack of specific details creates uncertainty and potential risk for investors.

Key Players & Entities

  • ORAMED PHARMACEUTICALS INC. (company) — Registrant
  • March 14, 2024 (date) — Earliest event reported
  • March 19, 2024 (date) — Filing date
  • 1185 Avenue of the Americas, Third Floor, New York, New York 10036 (location) — Principal Executive Offices

FAQ

What specific event is reported in this 8-K filing by Oramed Pharmaceuticals Inc.?

The filing is categorized under 'Other Events' and does not provide specific details about the nature of the event.

When was the earliest event reported in this filing?

The earliest event reported was on March 14, 2024.

On what date was this 8-K filing submitted to the SEC?

The filing was submitted on March 19, 2024.

Where are Oramed Pharmaceuticals Inc.'s principal executive offices located?

The principal executive offices are located at 1185 Avenue of the Americas, Third Floor, New York, New York 10036.

What is the Commission File Number for Oramed Pharmaceuticals Inc.?

The Commission File Number for Oramed Pharmaceuticals Inc. is 001-35813.

Filing Stats: 845 words · 3 min read · ~3 pages · Grade level 13.9 · Accepted 2024-03-19 08:00:39

Key Financial Figures

  • $0.012 — ch registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, Te
  • $101,875,000 — of issuance in the principal amount of $101,875,000 (the "Note"), as well as certain warran
  • $5 million — received the first principal payment of $5 million on December 21, 2023. Pursuant to the t
  • $15 million — e Note, the second principal payment of $15 million is due on March 21, 2024. On March 14,
  • $11.5 million — he Company received an early payment of $11.5 million and on March 18, 2024, an early payment
  • $3.5 million — on March 18, 2024, an early payment of $3.5 million. The third principal payment in the am
  • $20 million — hird principal payment in the amount of $20 million is expected to be paid on June 21, 2024

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORAMED PHARMACEUTICALS INC. By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and CEO March 19, 2024 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.